Literature DB >> 9711447

Current guidelines for the drug treatment of ankylosing spondylitis.

E Toussirot1, D Wendling.   

Abstract

Ankylosing spondylitis (AS) is a systemic inflammatory rheumatic disease involving spinal and sacroiliac joints. This condition is responsible for back pain, stiffness and discomfort. Several drugs are currently available in the management of AS, and may be divided into 3 groups. The first includes nonsteroidal anti-inflammatory drugs (NSAIDs), which are the main drug group used in AS because they reduce pain and stiffness in most patients. Several NSAIDs are available but phenylbutazone is considered the NSAID of choice in AS. However, other NSAIDs give similar beneficial results and the medication of preference in specific to each patient. All NSAIDs share common gastrointestinal toxicity, and they should be administered during periods of flare-up of the disease. The second drug group that has been used in the treatment of patients with AS comprises analgesics, muscle relaxants and low dose corticosteroids. They can be considered as adjuvant therapy. These drugs are helpful when NSAIDs are poorly tolerated or ineffective. Second-line treatments or disease modifying antirheumatic drugs (DMARDs) are included in the third group. These drugs are required in cases of longstanding severe or refractory AS. Sulfasalazine has proven to be effective in such cases, leading to improvement in clinical and laboratory indices of disease activity. Beneficial results are mainly evident in patients with AS who have peripheral disease involvement. Other medications (such as methotrexate or gold salts, for instance) require properly designed controlled studies to evaluate their effectiveness in the treatment of this disorder, while immunosuppressive agents have little to offer in the management of patients with AS and require further studies. Some specific clinical features are observed in AS: enthesopathy may be treated with local injection of corticosteroids; sacroiliac joint pain may be managed by corticosteroid injection performed under fluoroscopic control or guided by computed tomography. The management of patients with AS includes some other procedures such as patient education, rest, a programme of physical exercise and physiotherapy. In parallel with pharmacotherapy, these procedures are of great importance in reducing stiffness and spinal ankylosis, and thus improve the patient's quality of life.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9711447     DOI: 10.2165/00003495-199856020-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  107 in total

1.  Letter: Penicillamine in ankylosing spondylitis.

Authors:  Y Scharf; M Nahir
Journal:  Arthritis Rheum       Date:  1976 Jan-Feb

2.  Effect of physiotherapy on spinal mobility in ankylosing spondylitis.

Authors:  J V Viitanen; J Suni; H Kautiainen; M Liimatainen; H Takala
Journal:  Scand J Rheumatol       Date:  1992       Impact factor: 3.641

3.  A case of HLA-B27 negative ankylosing spondylitis treated with methylprednisolone pulse therapy.

Authors:  S Yoshida; Y Motai; H Hattori; H Yoshida; K Torikai
Journal:  J Rheumatol       Date:  1993-10       Impact factor: 4.666

4.  Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone.

Authors:  J W Boersma
Journal:  Scand J Rheumatol       Date:  1976       Impact factor: 3.641

5.  Double-blind comparison of tolmetin sodium and indomethacin in ankylosing spondylitis.

Authors:  J Esdaile; R Rothwell; K MacLaughlin; J Percy; D Hawkins
Journal:  J Rheumatol       Date:  1982 Jan-Feb       Impact factor: 4.666

Review 6.  Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.

Authors:  M A Peppercorn
Journal:  Ann Intern Med       Date:  1984-09       Impact factor: 25.391

7.  Compliance monitoring of NSAID drug therapy in ankylosing spondylitis, experiences with an electronic monitoring device.

Authors:  E de Klerk; S J van der Linden
Journal:  Br J Rheumatol       Date:  1996-01

8.  Frequency of atlantoaxial subluxation and neurologic involvement in patients with ankylosing spondylitis.

Authors:  C Ramos-Remus; A Gomez-Vargas; J L Guzman-Guzman; F Jimenez-Gil; J I Gamez-Nava; L Gonzalez-Lopez; H Farrera-Gamboa; W P Maksymowych; M E Suarez-Almazor
Journal:  J Rheumatol       Date:  1995-11       Impact factor: 4.666

9.  A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis.

Authors:  A Calin; J Elswood
Journal:  J Rheumatol       Date:  1990-06       Impact factor: 4.666

10.  Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with indomethacin.

Authors:  P L Lomen; L F Turner; K R Lamborn; E L Brinn
Journal:  Am J Med       Date:  1986-03-24       Impact factor: 4.965

View more
  14 in total

Review 1.  Rationale for the use of cyclooxygenase-2-specific nonsteroidal anti-inflammatory drugs in ankylosing spondylitis: the available evidence.

Authors:  Lars Köehler; Jens G Kuipers; Henning Zeidler
Journal:  Curr Rheumatol Rep       Date:  2003-06       Impact factor: 4.592

Review 2.  Clinical observations programme in SpA: disease parameters, treatment options and practical management issues.

Authors:  Dirk Elewaut; Filip Van den Bosch; Gust Verbruggen; Filip de Keyser; Bert Vander Cruyssen; Herman Mielants
Journal:  Rheumatol Int       Date:  2008-09-26       Impact factor: 2.631

Review 3.  Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population.

Authors:  Zhi-han Li; Yang Zhang; Jian Wang; Zhan-jun Shi
Journal:  Eur J Orthop Surg Traumatol       Date:  2012-06-29

Review 4.  Late-onset ankylosing spondylitis and spondylarthritis: an update on clinical manifestations, differential diagnosis and pharmacological therapies.

Authors:  Eric Toussirot
Journal:  Drugs Aging       Date:  2010-07-01       Impact factor: 3.923

Review 5.  Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations.

Authors:  Éric Toussirot
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

Review 6.  Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options.

Authors:  Eric Toussirot; Daniel Wendling
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 7.  Expanding the armamentarium for the spondyloarthropathies.

Authors:  Paul M Peloso; Jürgen Braun
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

8.  Short term in-patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice.

Authors:  Siv Grødal Eppeland; Andreas P Diamantopoulos; Dag Magnar Soldal; Glenn Haugeberg
Journal:  BMC Res Notes       Date:  2013-05-07

Review 9.  Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches.

Authors:  Juergen Braun; Joachim Sieper
Journal:  Arthritis Res       Date:  2002-08-06

10.  Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.

Authors:  Proton Rahman; Denis Choquette; William G Bensen; Majed Khraishi; Andrew Chow; Michel Zummer; Saeed Shaikh; Maqbool Sheriff; Sanjay Dixit; Dalton Sholter; Eliofotisti Psaradellis; John S Sampalis; Vincent Letourneau; Allen J Lehman; François Nantel; Emmanouil Rampakakis; Susan Otawa; May Shawi
Journal:  BMJ Open       Date:  2016-04-05       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.